Abstract
M O N D A Y 710 Effective Nasal Symptom Relief and Improvement in HealthRelated Quality of Life in Subjects with Perennial Allergic Rhinitis Following 6-Week Once-Daily Treatment with Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol W. Carr, E. O. Meltzer, A. Finn, P. M. Dorinsky, L. Kelley, S. A. Dunbar, S. K. Tantry; Allergy and Asthma Associates of Southern California Medical Group, Mission Viejo, CA, Allergy and Asthma Medical Group & Research Center, San Diego, CA, National Allergy, Asthma & Urticaria Centers of Charleston, Charleston, SC, Teva Branded Pharmaceutical Products RD P50.001). Moreover, for all 7 individual domains of the RQLQ, improvements from baseline were greater with BDP HFA than with placebo. Treatment with BDPHFA also resulted in a greater reduction from baseline in the average PNSS versus placebo (-1.22 [95% CI: -1.7, -0.7]; P<0.001). Greater improvements were also seen for individual physician-assessed nasal symptoms (nasal congestion, nasal itching, rhinorrhea, and sneezing) with BDP HFA than with placebo. CONCLUSIONS: This study demonstrated that BDP HFA nasal aerosol provides substantial relief of nasal symptoms and significant improvements in QOL in subjects with PAR. Thus, BDP HFA nasal aerosol should provide a new and effective treatment option for patients with PAR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
